Literature DB >> 18937616

Management of bile duct tumors.

Daniel Seehofer1, Carsten Kamphues, Peter Neuhaus.   

Abstract

Cholangiocarcinomas are a rare but highly fatal disease. The only curative treatment is radical surgical resection of the tumor and the regional lymph nodes. More than half of patients have irresectable disease, which implicates a median survival of < 1 year. The mainstay of palliative treatment is endoscopic or percutaneous drainage of the biliary system. In patients with good performance status, palliative chemotherapy seems to provide some survival benefit together with an improved quality of life. No standard chemotherapy has been defined but gemcitabine monotherapy or the combination of gemcitabine with platin derivates or capecitabine seems to be more effective than other protocols. Additionally, photodynamic therapy has shown promising results and radiation might be helpful for localized disease. In a very selected population liver transplantation can also be an option.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18937616     DOI: 10.1517/14656566.9.16.2843

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

1.  New insights on cholangiocarcinoma.

Authors:  Manuela Gatto; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2010-03-15

2.  EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.

Authors:  Bo Tang; Jian Du; Yang Li; Fang Tang; Zhenran Wang; Songqing He
Journal:  Med Oncol       Date:  2014-10-04       Impact factor: 3.064

3.  Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer.

Authors:  Do Hyung Kim; Min-Dae Kim; Cheol-Woong Choi; Chung-Wook Chung; Seung Hee Ha; Cy Hyun Kim; Yong-Ho Shim; Young-Il Jeong; Dae Hwan Kang
Journal:  Nanoscale Res Lett       Date:  2012-01-27       Impact factor: 4.703

4.  A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma.

Authors:  Elisa Paolicchi; Paola Pacetti; Elisa Giovannetti; Andrea Mambrini; Massimo Orlandi; Francesco Crea; Antonello A Romani; Roberta Tartarini; Romano Danesi; Godefridus J Peters; Maurizio Cantore
Journal:  Oncol Lett       Date:  2013-09-02       Impact factor: 2.967

5.  Novel pH-sensitive nanoformulated docetaxel as a potential therapeutic strategy for the treatment of cholangiocarcinoma.

Authors:  Nan Du; Lin-Ping Song; Xiao-Song Li; Lei Wang; Ling Wan; Hong-Ying Ma; Hui Zhao
Journal:  J Nanobiotechnology       Date:  2015-02-27       Impact factor: 10.435

6.  Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial.

Authors:  Alexander Stein; Dirk Arnold; John Bridgewater; David Goldstein; Lars Henrik Jensen; Heinz-Josef Klümpen; Ansgar W Lohse; Björn Nashan; John Primrose; Silke Schrum; Jenny Shannon; Eik Vettorazzi; Henning Wege
Journal:  BMC Cancer       Date:  2015-07-31       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.